诺和锐30与诺和灵30R治疗2型糖尿病的临床疗效比较被引量：9

Comparative Study on Efficacy of Novomix 30 and Novolin 30R for Treatment of Type 2 Diabetes Mellitus

下载PDF

导出

摘要目的比较诺和锐30与诺和灵30R治疗2型糖尿病(T2DM)的疗效及不良反应。方法 60例T2DM患者随机分为诺和锐30组和诺和灵30R组,分别给予诺和锐30或诺和灵30R 2次/d治疗,治疗3个月后,观察血糖控制情况及低血糖发生情况。结果①治疗后两组患者空腹血糖(FPG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)均较治疗前明显下降(P<0.01),但诺和锐30组2hFPG、HbA1c下降更明显(P<0.05)。②在控制血糖更佳的同时,诺和锐30所需剂量较诺和灵30R减少(P<0.05)。③诺和锐30组低血糖发生率显著低于诺和灵30R组(P<0.05)。结论诺和锐30能更好地降低T2DM血糖水平,减少低血糖反应,减少胰岛素剂量。 Objective To compare the efficacy and adverse reaction of Novomix 30 and Novolin 30R in patients with type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes mellitus were divided into two groups at random, they were given Novomix 30 and Novolin 30R twice daily for 3 months, and blood glucose and hypoglycemia were observed. Results （1） FPG,2hPBG, HbAlc decreased significantly in the two groups after treatment than that before （P 〈 0.01 ）. In Novomix 30 group 2hPBG, HbAlc control was superior to Novolin 3OR. （2） Novomix30 group in controlling blood sugar was better at the same time, was needed to all doses reduction than Novolin 30R （ P 〈 0.05 ）. （3） The incidence of hypoglycemia was lower in Novomix 30 group （ P 〈 0.05 ）. Conclusion For patients with type 2 diabetes mellitus, Novomix 30 can better reduce blood glucose levels and the incidence of hypoglycemia, and can reduce the dosage of insulin.

作者曾智玲

机构地区桂林市中西医结合医院内分泌科

出处《中国现代医生》 2011年第21期88-89,共2页 China Modern Doctor

关键词诺和锐30 诺和灵30R 2型糖尿病 Novomix 30 Novolin 3OR Type 2 diabetes mellitus

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献5

1叶新华,杜云峰,高剑波,薛云,李德,成金罗.短期诺和锐强化治疗对初诊2型糖尿病患者胰岛β细胞功能的影响[J].中华糖尿病杂志（1006-6187）,2005,13(2):114-117. 被引量：87
2祝方,纪立农,韩学尧,朱宇,张红杰,周翔海,陈静,蔡晓陵,张明霞.短期胰岛素强化治疗诱导初诊2型糖尿病患者血糖长期良好控制的临床试验[J].中国糖尿病杂志,2003,11(1):5-9. 被引量：856
3李延兵,翁建平,许雯,陈小华,廖志红,姚斌,邓婉萍,欧香忠,胡国亮.短期持续胰岛素输注治疗对初诊2型糖尿病患者胰岛β细胞功能的影响[J].中国糖尿病杂志,2003,11(1):10-15. 被引量：777
4Khutsoane D, Sharma SK, Almustafa M, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study[J]. Diabetes Obes Metab,2008,10 ( 3 ): 212-222.
5Yang W, Gao Y, Liu G, et al. Biphasie insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study[J]. Curr Med Res Opin,2010,26 ( 1 ): 101-107.

二级参考文献22

1Weyer. Dificiency in AIR predict IGT and Type 2 diabetes. Diabetes Care, 2001,24 : 89-94.
2Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes, 1995,44: 1386-1391.
3Bruce DG, Chisholm DJ, Leonare H, et al. Physiological importance of deficiency in early prandial insulin secretion in non-in-sulin-dependent diabetes. Diabetes, 1988,37: 736-743.
4Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes, 1999,48: 99-105.
5Ilkova H, glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20:1353-1356.
6Walton C, Godsland IF, Proudler AJ, et al. Effect of body mass index and fat distribution on insulin sensitivity, secretion, and clearance in nonobese healthy men. J Clin Endocrinol Metab,1992,75: 170-175.
7Purrello F, Rabuazza AM. Metabolic factors that affect betacell function and survival. Diabet Nutr Metab, 2000, 13: 84-91.
8Sivitz WI. Lipotoxieity and glueotoxieity in type 2 diabetes. Effects on development and progression. Postgrad Med, 2001,109: 55-59,63-64.
9Lenhard M J, Reeves GD. Continous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med,2001,161: 2293-2300.
10Dupuy O, Mayaudon H, Palou M, et al. Optimized transient insulin infusion in uneontrolled type 2 Diabetes : Evaluation of a pragmatie attitude. Diabet Med, 2000,26 : 371-375.